AZT Update

Helquist, Michael
November 1986
Advocate;11/11/86, Issue 459, p23
Reports that the U.S. Food and Drug Administration has approved a plan to distribute azathioprine (AZT) to eligible AIDS patients. Criteria for people to gain access to free use of the drug; Amendment of the criteria to include subsets of people with AIDS.


Related Articles

  • Three New AIDS Drugs.  // Advocate;11/11/86, Issue 459, p23 

    Reports that the U.S. Food and Drug Administration has given special priority status to expedite decisions regarding the regulation of drugs for use in patients with AIDS. Use of the drugs CS-85, ST and D-penicillamine to treat AIDS; Initial immunosuppression with D-penicillamine.

  • Pipeline preview.  // Formulary;May2005, Vol. 40 Issue 5, p144 

    Presents actions taken by the U.S. Food and Drug Administration concerning certain drugs. Approvable designations; Recommendations for approval; Priority review; Fast-track designations.

  • FOREWORD. Esherick, Donald // Drug Therapy & Childhood Adolescent Disorders;2003, p9 

    When a new drug is developed, a pharmaceutical company usually intends that drug to treat a single disease or family of diseases. The U.S. Food and Drug Administration (FDA) reviews the company's research to determine if the drug is safe for use in the population at large and if it effectively...

  • Tysabri: no longer out of TOUCH in the US.  // Reactions Weekly;6/17/2006, Issue 1106, p3 

    Reports on the U.S. Food and Drug Administration approval of an application for the reintroduction of the drug Tysabri in the U.S. Bases of the reintroduction; Reason for the drug's suspension; Elements of the TOUCH program developed by the Administration's Peripheral and Central Nervous...

  • FDA Drug Approval to Change its Ways? Elliott, William T. // Infectious Disease Alert;May2008, Vol. 27 Issue 8, p1 

    The article reports on the issue regarding the need to change the drug approval process of the U.S. Food and Drug Administration (FDA). It states that such process is being scrutinized that mainly focused on the Prescription Drug User Fee Act (PDUFA), which requires deadlines for approval of the...

  • Drug name confusion may cause medication errors.  // Hem/Onc Today;6/10/2013, Vol. 14 Issue 11, p46 

    The article explores the warning issued by the U.S. Food and Drug Administration (FDA) on the incorrect use of non-proprietary name for ado-trastuzumab emtansine, which is nonproprietary name approved by the FDA for Kadcyla (Genentech).

  • Study: No link between drug approval speed and safety.  // Pharmaceutical Representative;Dec2005, Vol. 35 Issue 12, p12 

    The article discusses a research conducted by the Tufts Center for the Study of Drug Development which indicates that faster approval of new drugs by the U.S. Food and Drug Administration (FDA) has not increased the number of prescription drugs withdrawn for safety reasons in the U.S. There was...

  • The FDA Speeds Medical Treatments for Serious Diseases. Rados, Carol // FDA Consumer;Mar/Apr2006, Vol. 40 Issue 2, p9 

    Provides information on three distinct approaches developed by the U.S. Food and Drug Administration intended to make important treatments available to those who need them. Fast track designation of drugs; Accelerated approval; Priority review. INSET: Maintaining High Standards and Safety...

  • FDA in Political Cross-hairs. Agres, Ted // Drug Discovery & Development;Feb2008, Vol. 11 Issue 2, p10 

    The article discusses the issues concerning the drug policy, budget, and drug approval of the U.S. Food and Drug Administration (FDA). The author claims that the regulatory procedures for the implementation of new provisions are complicated and time-consuming. Many patient advocacy groups...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics